Business Description
Quratis Inc
ISIN : KR7348080003
Compare
Compare
Traded in other countries / regions
348080.Korea IPO Date
2023-06-15Description
Quratis Inc operates as a developer of vaccines and therapies designed to treat tuberculosis. The company develops youth and adults tuberculosis vaccines, messenger ribonucleic acids, and other related immune-related vaccines.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.28 | |||||
| Equity-to-Asset | 0.57 | |||||
| Debt-to-Equity | 0.56 | |||||
| Debt-to-EBITDA | -2.26 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -3.93 | |||||
| Beneish M-Score | -2.48 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 79.7 | |||||
| 3-Year EBITDA Growth Rate | 22.5 | |||||
| 3-Year EPS without NRI Growth Rate | 3.7 | |||||
| 3-Year FCF Growth Rate | 32.3 | |||||
| 3-Year Book Growth Rate | 58.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 42.38 | |||||
| 9-Day RSI | 48.25 | |||||
| 14-Day RSI | 48.46 | |||||
| 6-1 Month Momentum % | -41.96 | |||||
| 12-1 Month Momentum % | -67.35 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.66 | |||||
| Quick Ratio | 0.53 | |||||
| Cash Ratio | 0.39 | |||||
| Days Inventory | 86.93 | |||||
| Days Sales Outstanding | 0.15 | |||||
| Days Payable | 20.19 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -27 | |||||
| Shareholder Yield % | 7.87 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -1135.44 | |||||
| Operating Margin % | -2306.1 | |||||
| Net Margin % | -2078.47 | |||||
| FCF Margin % | -2404.86 | |||||
| ROE % | -73.61 | |||||
| ROA % | -24.09 | |||||
| ROIC % | -24.45 | |||||
| ROC (Joel Greenblatt) % | -26.09 | |||||
| ROCE % | -33.1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 63.24 | |||||
| PB Ratio | 1.5 | |||||
| Price-to-Tangible-Book | 1.53 | |||||
| EV-to-EBIT | -5.08 | |||||
| EV-to-EBITDA | -7.9 | |||||
| EV-to-Revenue | 91.89 | |||||
| EV-to-FCF | -3.76 | |||||
| Earnings Yield (Greenblatt) % | -19.68 | |||||
| FCF Yield % | -33.09 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers